[A26-08] Resmetirom (metabolic dysfunction-associated steatohepatitis) – Addendum to Project A25-117
Last updated 05.03.2026
Project no.:
A26-08
Commission:
Commission awarded on 27.01.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (fibrosis stages F2 to F3)
Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A26-08
| Project no. | Title | Status |
|---|---|---|
| A25-117 | Resmetirom (metabolic dysfunction-associated steatohepatitis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
05-03-2026 A G-BA decision was published.
G-BA documents on this decision